Skip to main content
Adjuvant nivo+ipilimumab fails in kidney cancer, in contrast to pembro
Primary tabs
•••
View
Get Stamp Tags
Published Locations
Breadcrumb
Home
Adjuvant nivo+ipilimumab fails in kidney cancer, in contrast to pembro
User login
Username
Password
Reset your password
Concept
Lead
score
Renal Cell Carcinoma
1
1
Biologic Therapy
0
0.8
Cancer
0
0.8
Thyroid Disease
0
0.76
Metastasis
0
0.65
Kidney Cancer
0
0.98
Immunotherapy
0
0.99
Surgery
0
0.4
Toxicology
0
0.39
Antineoplastic Drug
0
0.31
Kidney
0
0.24
Hypothyroidism
0
0.2
Tyrosine Kinase Inhibitor
0
0.19
Adjuvant Setting
0
0.16
Biomarker
0
0.16
Hand
0
0.16
Partial Nephrectomy
0
0.97
Distant Metastasis
0
0.11
VEGF Inhibitor
0
0.11
Adjuvant Therapy
0
0.96
Europe
0
0.08
Fatigue
0
0.08
Histology
0
0.08
Match
0
0.08
Medical Oncology
0
0.08
New York
0
0.08
Pruritus
0
0.08
Radical Nephrectomy
0
0.08
Resection
0
0.08
Residual Disease
0
0.08
Tumor
0
0.08
Tyrosine Kinase
0
0.08
Vascular Endothelial Growth Factor
0
0.08
Diarrhea
0
0.07
Hyperthyroidism
0
0.07
Specialty
Lead
score
Hematology-Oncology
1
1
Internal Medicine
0
0.9
Edit Tags